Logo image of AKCA

Akcea Therapeutics Inc (AKCA) Stock Price, Quote, News and Overview

NASDAQ:AKCA - Nasdaq -

18.17  +0.03 (+0.17%)

After market: 18.15 -0.02 (-0.11%)

AKCA Quote, Performance and Key Statistics

Akcea Therapeutics Inc

NASDAQ:AKCA (10/9/2020, 8:24:15 PM)

After market: 18.15 -0.02 (-0.11%)

18.17

+0.03 (+0.17%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High21.71
52 Week Low8
Market Cap1.85B
Shares101.60M
Float94.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPON/A N/A


AKCA short term performance overview.The bars show the price performance of AKCA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

AKCA long term performance overview.The bars show the price performance of AKCA in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6

The current stock price of AKCA is 18.17 null. In the past month the price increased by 0.17%. In the past year, price decreased by -8%.

Akcea Therapeutics Inc / AKCA Daily stock chart

About AKCA

Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Company Info

Akcea Therapeutics Inc

22 BOSTON WHARF RD 9TH FLOOR

BOSTON MA 02210

CEO: Damien McDevitt

Phone: 617-207-0202

Akcea Therapeutics Inc / AKCA FAQ

What is the stock price of Akcea Therapeutics Inc today?

The current stock price of AKCA is 18.17 null. The price increased by 0.17% in the last trading session.


What is the ticker symbol for Akcea Therapeutics Inc stock?

The exchange symbol of Akcea Therapeutics Inc is AKCA and it is listed on the Nasdaq exchange.


On which exchange is AKCA stock listed?

AKCA stock is listed on the Nasdaq exchange.


What is Akcea Therapeutics Inc worth?

Akcea Therapeutics Inc (AKCA) has a market capitalization of 1.85B null. This makes AKCA a Small Cap stock.


What are the support and resistance levels for Akcea Therapeutics Inc (AKCA) stock?

Akcea Therapeutics Inc (AKCA) has a support level at 18.14 and a resistance level at 18.18. Check the full technical report for a detailed analysis of AKCA support and resistance levels.


Should I buy Akcea Therapeutics Inc (AKCA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does Akcea Therapeutics Inc (AKCA) stock pay dividends?

AKCA does not pay a dividend.


What is the Price/Earnings (PE) ratio of Akcea Therapeutics Inc (AKCA)?

Akcea Therapeutics Inc (AKCA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).


AKCA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to AKCA. When comparing the yearly performance of all stocks, AKCA is one of the better performing stocks in the market, outperforming 76.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AKCA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to AKCA. AKCA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AKCA Financial Highlights

Over the last trailing twelve months AKCA reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 65.82% compared to the year before.


Industry RankSector Rank
PM (TTM) -12.34%
ROA -7.86%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-60%
Sales Q2Q%-15.95%
EPS 1Y (TTM)65.82%
Revenue 1Y (TTM)53.07%

AKCA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 60% to AKCA. The Buy consensus is the average rating of analysts ratings from 3 analysts.


Ownership
Inst Owners0.01%
Ins Owners76.83%
Short Float %N/A
Short RatioN/A
Analysts
Analysts60
Price TargetN/A
EPS Next Y-445.83%
Revenue Next YearN/A